The prefrontal cortex as a target for atypical antipsychotics in schizophrenia, lessons of neurodevelopmental animal models

Prog Neurobiol. 2021 Apr:199:101967. doi: 10.1016/j.pneurobio.2020.101967. Epub 2020 Nov 30.

Abstract

Prefrontal cortex (PFC) inflammatory imbalance, oxidative/nitrosative stress (O/NS) and impaired neuroplasticity in schizophrenia are thought to have neurodevelopmental origins. Animal models are not only useful to test this hypothesis, they are also effective to establish a relationship among brain disturbances and behavior with the atypical antipsychotics (AAPs) effects. Here we review data of PFC post-mortem and in vivo neuroimaging, human induced pluripotent stem cells (hiPSC), and peripheral blood studies of inflammatory, O/NS, and neuroplasticity alterations in the disease as well as about their modulation by AAPs. Moreover, we reviewed the PFC alterations and the AAP mechanisms beyond their canonical antipsychotic action in four neurodevelopmental animal models relevant to the study of schizophrenia with a distinct approach in the generation of schizophrenia-like phenotypes, but all converge in O/NS and altered neuroplasticity in the PFC. These animal models not only reinforce the neurodevelopmental risk factor model of schizophrenia but also arouse some novel potential therapeutic targets for the disease including the reestablishment of the antioxidant response by the perineuronal nets (PNNs) and the nuclear factor erythroid 2-related factor (Nrf2) pathway, as well as the dendritic spine dynamics in the PFC pyramidal cells.

Keywords: Astrocytes; Dendritic spines; Developmental risk factor model of psychosis; Inflammation; Interneuron; Isolation rearing; Maternal immune activation; Methylazoxymethanol (MAM); Microglia; Neonatal ventral hippocampus lesion; Neuroplasticity; Pyramidal neuron; Synaptic pruning; oxidative/nitrosative stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use
  • Disease Models, Animal
  • Humans
  • Induced Pluripotent Stem Cells
  • Prefrontal Cortex
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents